Journal
SAUDI PHARMACEUTICAL JOURNAL
Volume 31, Issue 1, Pages 119-124Publisher
ELSEVIER
DOI: 10.1016/j.jsps.2022.11.010
Keywords
Anticoagulation; Cost effectiveness; Atrial fibrillation; Rivaroxaban; Warfarin
Categories
Ask authors/readers for more resources
Through retrospective chart review, it was found that rivaroxaban is cost-effective in reducing hospitalization and mortality risks compared to warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia.
Background: Rivaroxaban is a novel oral anticoagulant (NOAC) that is commonly used for stroke preven-tion among patients with atrial fibrillation (AF). However, its cost effectiveness in reducing the risk of hospitalization and mortality in comparison to warfarin among nonvalvular AF patients in Saudi Arabia is largely unknown. Methods: This was a single-center retrospective chart review of adult patients (>= 18 years) with nonva-lvular AF who were treated with warfarin or rivaroxaban for at least 12 months. Patients with mitral valve stenosis were excluded from the study. Multiple logistic regression was conducted to examine the risk of hospitalization and mortality as a composite outcome, and all annual healthcare costs were captured. Inverse probability treatment weighting with bootstrapping was conducted to determine the mean costs and effectiveness rates. Results: Two-hundred and twenty-six patients (142 on rivaroxaban and 84 on warfarin) met the inclu-sion criteria and were included in the analysis. Most of the patients were females (65.91 %), had diabetes (50.57 %) and hypertension (73.76 %), and with a mean age of 68.95 +/- 12.55 years. No significant differ-ence in the odds of the composite outcome for rivaroxaban versus warfarin was found (OR = 0.785, 95 % CI = [0.427-1.446], p = 0.443). Rivaroxaban resulted in a mean annual cost saving of $13,260.79 with an 87.65 % confidence level that it would be more effective than warfarin with a mean difference in effec-tiveness rate of 0.168 % (95 % CI [-5.210-18.36]). Conclusion: Rivaroxaban was associated with lower direct medical costs and non-inferior effectiveness among nonvalvular AF patients in comparison to warfarin. (c) 2022 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available